Aastrom Biosciences to Present at BIO Investor Forum
October 12 2006 - 4:00PM
PR Newswire (US)
ANN ARBOR, Mich., Oct. 12 /PRNewswire-FirstCall/ -- Aastrom
Biosciences, Inc. (NASDAQ:ASTM) today announced that George W.
Dunbar, President and Chief Executive Officer, will be presenting
at the 2006 BIO Investor Forum. The Investor Forum will be held
October 18-19th at the Palace Hotel in San Francisco, California.
Mr. Dunbar will present on Thursday, October 19, 2006 at 2:00 p.m.
(Pacific Time). (Logo:
http://www.newscom.com/cgi-bin/prnh/20060302/NETH028LOGO ) A live
webcast of Aastrom's presentation can be accessed by logging onto
the web at
http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=ASTM&item_id=1400451.
A replay of the presentation will be archived until the conclusion
of the conference on October 19th, at the same site. For more
information, please visit the conference website at
http://investorforum.bio.org/opencms/bif/2006/index.jsp . About
Aastrom Biosciences, Inc. Aastrom Biosciences, Inc. (NASDAQ:ASTM)
is developing autologous cell products for the repair or
regeneration of multiple human tissues, based on its proprietary
Tissue Repair Cell (TRC) technology. Aastrom's TRC-based products
are a unique cell mixture containing stromal, stem and progenitor
cell populations, produced outside the body from a small amount of
bone marrow taken from the patient. TRC-based products have been
used in over 225 patients, and are currently in clinical trials for
bone regeneration (long bone fractures and spine fusion) and
vascular regeneration (critical limb ischemia) applications. The
Company has reported positive interim clinical trial results for
TRCs suggesting both the clinical safety and the ability of TRCs to
induce tissue regeneration in long bone fractures and jaw bone
reconstruction. Recently, the Company's proprietary TRCs received
an Orphan Drug Designation from the U.S. Food and Drug
Administration (FDA) for use in the treatment of osteonecrosis of
the femoral head. In addition, Aastrom is developing plans for a
TRC-based therapy for cardiac regeneration. For more information,
visit Aastrom's website at http://www.aastrom.com/ . This document
contains forward-looking statements, including without limitation,
statements regarding product development objectives, market
development plans, and potential advantages and applications of
Tissue Repair Cells, which involve certain risks and uncertainties.
The forward-looking statements are also identified through use of
the words "plans," and other words of similar meaning. Actual
results may differ significantly from the expectations contained in
the forward-looking statements. Among the factors that may result
in differences are the results obtained from clinical trial
activities, regulatory approval requirements, and the availability
of resources. These and other significant factors are discussed in
greater detail in Aastrom's Annual Report on Form 10-K and other
filings with the Securities and Exchange Commission. CONTACTS: Kris
M. Maly Cameron Associates Investor Relations Department Kevin
McGrath Aastrom Biosciences, Inc. Phone: (212) 245-4577 Phone:
(734) 930-5777 Deanne Eagle (Media) Phone: (212) 554-5463
http://www.newscom.com/cgi-bin/prnh/20060302/NETH028LOGO
http://photoarchive.ap.org/ DATASOURCE: Aastrom Biosciences, Inc.
CONTACT: Kris M. Maly, Investor Relations Department of Aastrom
Biosciences, Inc., +1-734-930-5777; or Kevin McGrath,
+1-212-245-4577, or Deanne Eagle (Media), +1-212-554-5463, both of
Cameron Associates Web site: http://www.aastrom.com/
http://investorforum.bio.org/opencms/bif/2006/index.jsp
Copyright
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Sep 2024 to Oct 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Oct 2023 to Oct 2024